Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Carcinoma, Transitional Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 35Nivolumab 14Docetaxel 11atezolizumab 10Paclitaxel 9Carboplatin 7Gemcitabine 6Cisplatin 6Trastuzumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5fludarabine 4avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4cemiplimab 3Taxes 3Polymerase Chain Reaction 3Pemetrexed 3Irinotecan 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × epacadostat × Genitourinary × Clear all
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Terminated
10 enrolled 14 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡